Wyeth Prempro DTC
Executive Summary
Wyeth expects to have DTC advertisements within the next several months to promote a lower dose of its hormone replacement therapy Prempro (.45 mg conjugated estrogens/1.5 mg medroxyprogesterone), which was launched July 1 after gaining FDA approval March 12 (1"The Pink Sheet" March 17, 2003, p. 4). Prempro .45 mg/1.5 mg is the middle dosing option in the Prempro franchise following the approval of the Prempro .3 mg/1.5 mg dose June 4 (2"The Pink Sheet" June 16, 2003, p. 35)...